Last reviewed · How we verify
IAP0971
At a glance
| Generic name | IAP0971 |
|---|---|
| Sponsor | SUNHO（China）BioPharmaceutical CO., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (PHASE1, PHASE2)
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (PHASE1, PHASE2)
- A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer (PHASE1, PHASE2)
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IAP0971 CI brief — competitive landscape report
- IAP0971 updates RSS · CI watch RSS
- SUNHO（China）BioPharmaceutical CO., Ltd. portfolio CI